These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35018242)

  • 41. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
    Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
    Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression, Clinical Significance, and Functional Prediction of MNX1 in Breast Cancer.
    Tian T; Wang M; Zhu Y; Zhu W; Yang T; Li H; Lin S; Dai C; Deng Y; Song D; Li N; Zhai Z; Dai ZJ
    Mol Ther Nucleic Acids; 2018 Dec; 13():399-406. PubMed ID: 30368216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.
    Kawaguchi T; Yan L; Qi Q; Peng X; Edge SB; Young J; Yao S; Liu S; Otsuji E; Takabe K
    Ann Surg Oncol; 2018 Dec; 25(13):4037-4046. PubMed ID: 30311168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular and Clinical Characterization of CCT2 Expression and Prognosis
    Liu Q; Qi Y; Kong X; Wang X; Zhang W; Zhai J; Yang Y; Fang Y; Wang J
    Front Oncol; 2021; 11():614497. PubMed ID: 33869000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
    Schulz GB; Grimm T; Sers C; Riemer P; Elmasry M; Kirchner T; Stief CG; Karl A; Horst D
    Urol Oncol; 2019 Aug; 37(8):530.e9-530.e18. PubMed ID: 31176613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
    Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
    Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
    Thomas A; Routh ED; Pullikuth A; Jin G; Su J; Chou JW; Hoadley KA; Print C; Knowlton N; Black MA; Demaria S; Wang E; Bedognetti D; Jones WD; Mehta GA; Gatza ML; Perou CM; Page DB; Triozzi P; Miller LD
    Oncoimmunology; 2018; 7(10):e1490854. PubMed ID: 30386679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RAD54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancer.
    Zhang Z; Li X; Han Y; Ji T; Huang X; Gao Q; Ma D
    Biomed Pharmacother; 2019 Oct; 118():109341. PubMed ID: 31545289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.
    Zheng F; Du F; Qian H; Zhao J; Wang X; Yue J; Hu N; Si Y; Xu B; Yuan P
    Biomark Res; 2021 Apr; 9(1):28. PubMed ID: 33926554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
    Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
    Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
    [No Abstract]   [Full Text] [Related]  

  • 58. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
    BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene expression patterns associated with p53 status in breast cancer.
    Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
    BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival.
    Kattan SW; Hobani YH; Shaheen S; Mokhtar SH; Hussein MH; Toraih EA; Fawzy MS; Abdalla HA
    Cell Mol Biol Lett; 2021 Apr; 26(1):14. PubMed ID: 33849428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.